Vaccine

The Cervipro Project progresses after a meeting in Heildelberg

The project devoted to the development of a cost-effective vaccine against cerivcal cancer, called Cervipro, continues progressing after the meeting held last week among Elena de la Torre, Project Manager at Bionaturis, and the representatives of the German Cancer Research Center (DKFZ) and the company BioEnergy GmbH & Consultant, as leaders of the consortium.

The meeting, held in the facilities of the research center in Heildelberg (Germany), was useful to monitor the contributions and actions of each member, as well as to set the next milestones in the development. Besides our Project Manager, Elena de la Torre, the attendees were Michael Götz (from BioEnergy GmbH & Consultant), Martin Müller and Caroline Odenwald (from DKFZ).

The goal of the Cervipro Project is to obtain a cost-effective vaccine against the Human Papilomavirus, which causes the cervical cancer. This project receives funding from the Eurostars-2 Programme with co-funding from CDTI and the Research and Innovation Horizon 2020 Framework Programme from European Union.

Taking part in an alternative strategy to produce the drug in a cost-effective way to make it affordable for the most highly impacted regions, Bionaturis Group is following its vision of ‘A Global Access To Health’.

About Bionaturis

Bionaturis Group offers cutting-edge biotechnological drugs and services for human and animal health. Considered an international benchmark in vaccines research, the biotechnological Group which envisions a global access to health is listed on the Spanish stock exchange for SMEs (ticker BNT).

February 4th, 2016|Blog english|Comments Off|

Bionaturis Group takes part in the development of a vaccine against cervical cancer

The Centre for the Development of Industrial Technology (CDTI, in Spanish) has granted an incentive of 184.847,40 Euros to the company from the European Programme Eurostars
The project is led by the German company BioEnergy GmbH & Consultant with participation from the German Cancer Research Center

Jerez de la Frontera, January 12nd 2016. Bionaturis Group will take part in the development of a cost-effective and possibly oral vaccine against cervical cancer. The initiative, led by the German company BioEnergy GmbH & Consultant with the participation of the German Cancer Research Center, receives funding from the Eurostars-2 Programme with co-funding from CDTI and the Research and Innovation Horizon 2020 Framework Programme from European Union.

According to the World Health Organization (WHO), developing countries suffer the highest impact from cervical cancer, which is caused by the Human Papillomavirus (HPV). Currently available vaccines are at a price point that makes them unaffordable for most people in developing countries. In addition to the loss of human lives, this circumstance leaves a large gap in the global coverage against the disease. With this project, Bionaturis Group is taking part in an alternative strategy to produce a cost-effective vaccine that will be affordable for the most highly impacted regions, following its vision of ‘A Global Access To Health’.

“This project is a real and relevant challenge for Bionaturis because, with it, we are expanding our horizons. Our acquired technological expertise in both vaccine development and cost effective manufacturing platforms lets us face this initiative with the realistic goal of providing to the population at risk a first-in-class drug that will be affordable given the social and economic conditions of their countries”, Bionaturis CSO, Juan Jose Infante, has stated.

The WHO highlights that cervical cancer caused […]

January 12th, 2016|Blog english, Press Releases|Comments Off|

By FLYLIFE vaccines against diseases as Ebola could be manufactured

Bionaturis (ticker BNT) scientists have analyzed the situation on protection against this disease which, unfortunately, is on the news in recent weeks. Based on the antigenic capacity in murine models of the glycoprotein of the Ebola virus capside (S1090, Journal of Infection Diseases, 2011:204 – Suppl. 3-, Tsuda et to the), Bionaturis team could develop a recombinant vaccine in its FLYLIFE system. Bionaturis would follow similar strategies already successfully used for other vaccine developments based on this type of protein within the company.

According to Dr Juan Jose Infante, CSO of the company, “there are data showing that, properly presented, this antigen may confer protection against the Ebola virus in healthy patients. Bionaturis has the track record and necessary knowledge in recombinant antigen presentation to pursue a high rate of success. On the other hand, unlike other options being considered, such as the use of an attenuated virus to carry this protein, a recombinant vaccine strategy would be much more safer during the production and handeling and would have less uncertainty regarding safety in healthy vaccinated humans. In the event of a successful development using FLYLIFE, thanks to its features, Bionaturis could release batches of million doses within four weeks upon order receipt. Dealing with any emergency the population at risk would be protected, guaranteeing total safety for the rest”.

Bionaturis scientists estimate that within a maximum of 24 months it would be viable to deliver experimental doses of a hipothetical  new vaccine, with proven safety and efficacy tested in animal models and ready to be tested in primates and humans, or to be used in cases of emergency as the occurred in the last month. Bionaturis´team is evaluating the possibilities of development of this vaccine along with its commercial and technological […]

August 19th, 2014|Blog english, Press english|Comments Off|

Bionaturis’ vaccine against Visceral Canine Leishmaniasis, preventive and therapeutic

Bionaturis continues the development of BNT005, a vaccine against Visceral Canine Leishmaniasis, a disease that affects dogs and is spread in Mediterranean countries as Spain, being registered an increasing rate of zoonosis (when an animal disease infects humans) lately. The visceral one is the most serious type of Leishmaniasis and it can be lethal if it is not treated well. It is caused by the parasites Leishmania and transmitted by the bite of the phlebotomine sandfly that acts as a vector.

Nowadays there is not any vaccine already in the market to prevent or treat humans against this disease, being its development a priority of the World Health Organization (WHO). The current treatment with antiparasitics has undesirable side effects and it causes the outbreak of resistance phenomena in the parasite. However, for dogs there are few options approved in Europe and LATAM, that claim themselves as prophylactic but not therapeutic.

Dogs among rabbits are the main reservoir of Leishmaniasis. Because of that, its control is essential to avoid the spread of this disease in humans (zoonosis). “A vaccine against canine Leishmaniasis has a double goal. Firstly, in the animals, which will be protected or can be treated against a disease that is fatal in a high percentage of cases. And, secondly, in humans, who will have less possibilities of suffering the disease if their pets do not have the parasite or they have them under control”, Bionaturis’ CSO, Juan Jose Infante, has stated.

Tests in rodents and Beagle dogs

Infante has also stood out that “the difference between BNT005 by Bionaturis and others vaccine attempts to fight this disease is that the preliminary results obtained and published in the last annual management report show that Bionaturis’ vaccine induces […]

August 12th, 2014|Blog english, Press english|Comments Off|

A veterinarian multinational company will test the Bionaturis vaccine against nematodes in livestock

Bionaturis (BNT-MAB), an international reference company developing biological vaccines, has signed a contract with a multinational veterinarian company that will test the efficacy and safety of a vaccine to prevent livestock to be infected by intestinal nematodes -helminthes-. This agreement endorses Bionaturis strategic position as a supplier of vaccines for the veterinarian industry.

These gastrointestinal parasites cause annual losses of 3,000 million Euros in the livestock industry. To combat their effects, companies are using chemical endoparasticides that gradually lose efficacy due to growing phenomena of resistance. For this reason among others, governments and sectorial organizations are recommending a reduction of their use. In preliminary in-vivo tests, Bionaturis vaccine has shown superb protection against the types of helminthes that cause more problems and phenomena of resistance in the field. This product, encoded by the company as BNT004, is a first-in-class preventive treatment, and it could become a real and safe option against the most serious cases of resistance.

Efficacy higher than 65% in mice and lamb trials

BNT004 has already been tested in mice and lamb trials, showing protection values higher than 65%, in all cases, about the reduction of the number of parasites in vaccinated animals versus control. Besides, the vaccine is 100% safe and the treated animals did not show any symptomatology. As outstanding outcome for the livestock industry, challenged and vaccinated animals did not show a loss of weight versus control animals, whereas the challenged un-vaccinated animals did.

BNT004 is protected by a patent application of University of Granada (UGR), active in the main traditional veterinarian markets, out-licensed exclusively to Bionaturis back in 2012. Next trials will be made in the multinational company facilities and they will be finished in the first semester of 2014.

Javier Gallestegui, […]

A multinational veterinarian company will test Bionaturis’s vaccine for salmons

Bionaturis (BNT-MAB), an international reference company developing vaccines for aquiculture, has signed a contract with a multinational veterinarian company to evaluate the efficacy and safety of a FLYLIFE-produced vaccine intended to be used against the most devastating diseases affecting the salmon industry.

During the first half (H1) of 2014 the multinational company will perform in vivo exploratory trials in salmons. The salmon industry is, along with the carp one, one of the biggest aquiculture industries in the world, having reached annual figures greater than 11 billion dollars since 2007. Norway with 33% and Chile with 31% lead world production. Throughout history, several episodes of pandemics, mainly of the ISA (Infectious Salmon Anemia) virus, have generated significant losses. Because of that, the search of new prevention and therapeutic solutions to fight those diseases affecting the sector is one of the salmon industry priorities.

Javier Gallastegui, managing director of Bionaturis, states: “the worldwide positioning we have achieved as a supplier of aquaculture vaccines is confirmed with contracts of this kind. If the trials are successful we could get incomes between 10 and 15 million dollars in royalties in the years following the vaccine launch to the market”.Bionaturis (BNT-MAB), an international reference company developing vaccines for aquiculture, has signed a contract with a multinational veterinarian company to evaluate the efficacy and safety of a FLYLIFE-produced vaccine intended to be used against the most devastating diseases affecting the salmon industry.

During the first half (H1) of 2014 the multinational company will perform in vivo exploratory trials in salmons. The salmon industry is, along with the carp one, one of the biggest aquiculture industries in the world, having reached annual figures greater than 11 billion dollars since 2007. Norway with 33% and […]

Bionaturis signs agreement with a multinational animal health company

Through the material transfer agreement –MTA- the veterinarian company will test a vaccine produced by the Bionaturis´ FLYLIFE.
It is a strategic milestone of the Spanish Biotech company for the development and achievement of its business plan.
The agreement involves an exclusive out-license option for the big laboratory and give access to Bionaturis to an international market of large numbers.

Bionaturis (BNT-MAB) has signed a strategic Material Transfer Agreement (MTA) with a multinational veterinarian company to evaluate the efficacy and safety of a vaccine produced by means of Flylife system. The multinational will execute in vivo exploratory trials of the vaccine over the intended animal of protection. The agreement also includes options of exclusive in-licensing rights for the veterinarian company.
According to Victor Infante -CEO of Bionaturis- statements “this contract represents a major milestone for out-licensing our current portfolio (BNTs) as well as our Flylife system. The confidence of multinational partners is key to our business model. This agreement is a strategic step for our growth and we will announce other similar in the forthcoming months.”

Bionaturis shed light on the oral vaccines for fish farming in Chile

The Andean country was affected in 2007 by one of the worst crises in the sector by ISA virus, causing a significant damage to its economic potential. Today, aquaculture companies have adopted new measures and still looking for cost-effective preventive solutions. In this sense, the International Workshop on “Immunology, diagnostic and therapies against infectious agents in the salmon industry” took place in Puerto Varas (21-22 march).
Renowned international experts have focused their attention on the major pathogens affecting the farmed fish: such as ISA virus (and more recently, Caligus pathogens). The assistants have agreed to step up cooperation in the key areas against infectious agents in Chile’s salmon farming industry, which today produces 840.000 tons.
Bionaturis, represented by Ph.D. Ana de las Heras has much to contribute to this endeavor, being an international reference on oral vaccines to be used in fish farming. The company shared their exclusive patented system, Flylife that was applauded by the experts. Bionaturis, with their proprietary formulations of oral-administrated vaccines, has proven to be ready to tackle effectively the challenges of this industry and to offer real solutions to the producers.

  • Permalink Gallery

    Bionaturis to tackle the protection of fish farms with oral vaccines

Bionaturis to tackle the protection of fish farms with oral vaccines

Aquaculture is a booming national industry. The total turnover in Spain alone stands at nearly 500 million euros, where Andalusia with 55 million euros accounts for 11% 
The AQUAFLY project, based on the Bionaturis FLYLIFE production system, will be deployed in collaboration with the Department of Chemical Engineering, Food Technology and Environmental Sciences, at the Science Faculty of Cadiz University; and CTAQUA (Andalusian Aquaculture Technological Centre Foundation).
Ana de las Heras from Bionaturis, who holds a PhD in Veterinary Science, is the Project leader, an initiative that will last 3 years and is co-funded by Corporación Tecnológica de Andalucía (CTA).

Jerez de la Frontera, 21 December 2012. Bionaturis, a biotechnological company listing  on the Spanish Alternative Investment Market (MAB), has embarked on the Aquafly project in collaboration with the Department of Chemical Engineering, Food Technology and Environmental Sciences, at the Science Faculty of Cadiz University; and CTAQUA (Andalusian Aquaculture Technological Centre Foundation).  The project aims to research more efficient vaccination alternatives for farmed fish..
Oral vaccines, a breakthrough for the sector
The idea for the project emerged from the Bionaturis internal aquaculture R&D team after analysing the sector’s needs in the meetings recently held between  international and national producers and veterinary companies. The technical goal is to design  and develop new oral therapeutic and prophylactic vaccines, based on the cutting-edge FLYLIFE production system  (using insect larva as bioreactors to produce biological drugs), which can be used more safety and efficiently to protect against major diseases that currently affect aquaculture. The research programme, which will run for three years, is led by Ana de las Heras, a Bionaturis scientific researcher with a PhD in Veterinary Sciences. This project is being cofunded by Corporación Tecnológica de Andalucía (CTA).
Importance of the industry: […]

The solution for a fast and affordable access to animal health

El Colegio Oficial de Veterinarios de Sevilla se hace eco de la participación de Bionaturis en el IX Congreso Internacional de Virología Veterinaria.

Publicación del Colegio Oficial de Veterinarios de Sevilla

September 14th, 2012|Press english|0 Comments|

Uso de cookies

Este sitio web utiliza cookies para que usted tenga la mejor experiencia de usuario. Si continúa navegando está dando su consentimiento para la aceptación de las mencionadas cookies y la aceptación de nuestra política de cookies, pinche el enlace para mayor información.

CERRAR